Your Health, We Care
Release date: 2024-08-16 17:45:46 Recommended: 112
Selpercatinib treats cancer patients by specifically inhibiting RET kinase activity. In 2020, it was approved for marketing in United States, becoming the first drug specifically targeting RET gene mutations. The drug has shown significant efficacy against a variety of RET-related cancers.
In terms of therapeutic efficacy, Selpercatinib showed the following significant improvements.
Patients with previously treated RET fusion-positive non-small cell lung cancer
247 patients, 16 of whom had measurable central nervous system (CNS) metastases at baseline.
Fourteen patients (88% of patients with CNS metastases at baseline or approximately 6% of the total study population) experienced a treatment response to intracranial lesions, demonstrating the effectiveness of this treatment for brain metastases.
Among patients who responded to intracranial lesions, 39% had a duration of intracranial remission of 12 months or more, demonstrating the durability of treatment in controlling brain metastases.
Special attention needs to be paid to the use of drugs in special populations, and the following are relevant guidance and recommendations.
For patients with mild to severe renal insufficiency, current research and clinical experience suggest that no drug dose adjustment is required. Patients can take the drug in standard doses, and kidney function should be monitored regularly during treatment to detect and treat possible kidney-related problems in a timely manner.
When using this drug in elderly patients, no other specific clinical problems were observed. The physiological characteristics of the elderly may affect drug metabolism and tolerance, and it is recommended to use it under the guidance of a doctor to ensure the effectiveness of treatment.
There are a few important things to note when using Selpercatinib, as knowing what to do and don't need can help patients manage their treatment progress.
Acute or worsening respiratory symptoms should be withheld and interstitial lung disease should be investigated. After diagnosis, the dose is adjusted or discontinued according to the condition.
Patients at risk for QT interval prolongation should be monitored, particularly those with arrhythmias or a history of severe heart failure. The QT interval and electrolyte levels are assessed regularly before and during treatment, and the frequency of monitoring is adjusted according to risk.
[Warm tips] Do not stop or adjust your medication on your own. If you feel that the drug is not working well or has side effects, you should contact your doctor in time to adjust the regimen.
